HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant

BACKGROUND: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast cancer (BrCa). A truncated p95HER2 variant lacking the trastuzumab bindin...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gynecol Oncol
Prif Awduron: Growdon, Whitfield B., Groeneweg, Jolijn, Byron, Virginia, DiGloria, Celeste, Borger, Darrell R., Tambouret, Rosemary, Foster, Rosemary, Chenna, Ahmed, Sperinde, Jeff, Winslow, John, Rueda, Bo R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380649/
https://ncbi.nlm.nih.gov/pubmed/25602714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.01.533
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg